Novo Nordisk to reduce insulin prices by up to 75% in the US
The Danish drugmaker is following the lead of Eli Lilly after being urged on by Vermont Senator Bernie Sanders.
by marketwire, translated by daniel pedersen
Novo Nordisk is joining the group of pharmaceutical companies that are planning to lower insulin prices after being urged on by Vermont Senator Bernie Sanders, who chairs the US Senate Committee on Health. The move will make diabetes treatment more accessible in the country.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Eli Lilly to lower insulin prices by 70% in US
For subscribers
.jpg&w=384&q=75)
